advertisement

Hashida, who wrote 'Oshin,' many other hit dramas dies at 95

TOKYO (AP) - Renowned Japanese scriptwriter Sugako Hashida, best known for the internationally popular TV drama series 'œOshin," has died of lymphoma. She was 95.

Hashida had been treated for the illness since earlier this year. She died Sunday at her home in Atami, west of Tokyo, according to Pinko Izumi, an actress who appeared in many of the dramas Hashida wrote, including 'œOshin."

Born in Korea in 1925 during the Japanese colonization of the Korean Peninsula, Hashida moved to Japan in the late 1930s and lived those early years in Osaka.

She joined the Shochiku film studio in 1949 before becoming a freelance scriptwriter for television dramas, including the hugely popular morning drama series 'œOshin'ť broadcast in 1983-1984 on NHK public television.

The fictionalized drama is based on the biography of a Japanese woman who co-founded a famous supermarket chain and her multiple hardships from her childhood until her final days in the 1980s.

'œOshin'ť was broadcast in more than 60 countries and gained high acclaim.

Her other popular dramas included "Wataru Seken wa Oni Bakari," or 'œMaking it Through,'ť a family drama series that started in 1990 and aired more than 500 episodes.

Actress Izumi, who was in both 'œOshin'ť and 'œWataru Seken wa Oni Bakari,'ť said she was at Hashida's bedside when she died.

'œI said to her '~Mama,' then she briefly opened her eyes, then it was as if she went back to sleep," Izumi said in an interview with Japanese media.

Hashida wrote a book asking for the right to die in dignity. According to her request, there will be no funeral.

Hashida received the Japan Order of Culture last year.

Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.